This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

OPSYNVI - The A DUE Phase 3 Trial

Last Updated: 02/04/2025

Summary

A summary of this response is provided as an interactive PDF (iPDF) that can be accessed by clicking the following link:

  • OPSYNVI® (macitentan and tadalafil) - The A DUE Phase 3 Trial
    • Minimum requirement to access interactive content: Adobe Acrobat Reader
  • The executive summary infographic of the iPDF content is provided below